2019 FDA Approval Process Chemistry Therapies 
Metabolite Tales Blog
JULY 5, 2023
Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. A combination therapy of glecaprevir and pibrentasvir has recently been implicated in a case of liver injury. Balazs et al., Drug Hunter article, June 2023.
Metabolite Tales Blog
JULY 5, 2023
Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. A combination therapy of glecaprevir and pibrentasvir has recently been implicated in a case of liver injury. Balazs et al., Drug Hunter article, June 2023.
Expert insights. Personalized for you.
52 
Let's personalize your content